2021: Laronde raises $440m to develop treatments with infinite RNA
In August 2021, Laronde, a biotech start-up backed by venture capital firm Flagship Pioneering Inc that helped create Moderna, raised $440 million in a funding round to develop new treatments using so-called infinite RNA.
Similar to messenger RNA technology, which is used in vaccines from Moderna and other drug manufacturers, endless RNA can transmit detailed instructions to cells to create proteins.
According to Laronde executives, the difference between eRNA (endless RNA) is that its circular shape allows it to repeat its message over and over again, which provides a more powerful and lasting impact. This key feature can prevent rapid destruction of the body, making it an attractive candidate for treating diseases.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |